Varaico: Literature-Extracted Genetic Variants

Gene:GLA
Variant:p.F396Y
Back to variants list

GLA

NM_000169.3:p.F396Y

Associated Papers

Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease.

Lukas J et al.

International Journal of Molecular Sciences, 2020

High-risk screening for Anderson-Fabry disease in patients with cardiac, renal, or neurological manifestations.

Nakagawa N et al.

Journal of Human Genetics, 2019

Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase.

Cimmaruta C et al.

Bmc Bioinformatics, 2018

30497360 (PubMed )
Supplement: 12859_2018_2416_MOESM1_ESM.xlsx › ST1

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

Benjamin ER et al.

Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017

27657681 (PubMed )
Supplement: gim2016122x1.zip › Supplemental_Appendix_2_12152015.xlsx › Unknown

The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.

Citro V et al.

International Journal of Molecular Sciences, 2016

27916943 (PubMed )
Supplement: ijms-17-02010-s001.zip › ijms-157565-supplementary_file_1_done.xlsx › Tabella_aggiornamento

Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.

Germain DP et al.

The New England Journal of Medicine, 2016

27509102 (PubMed )
Supplement: nejmoa1510198_protocol.pdf

Screening of male dialysis patients for fabry disease by plasma globotriaosylsphingosine.

Maruyama H et al.

Clinical Journal of the American Society of Nephrology : Cjasn, 2013

Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease.

Lukas J et al.

Plos Genetics, 2013

Novel tools for extraction and validation of disease-related mutations applied to Fabry disease.

Kuipers R et al.

Human Mutation, 2010

20629180 (PubMed )
Supplement: supplement_1.pdf

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.

Garman SC et al.

Journal of Molecular Biology, 2004

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."